Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses

Cancer Immunology, Immunotherapy

Volumn 60, Issue 12, 2011, Pages 1775-1787

  Smith, Shannon E ^a   Hoelzinger, Dominique B ^a   Dominguez, Ana Lucia ^a   Van Snick, Jacques ^b   Lustgarten, Joseph ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

4 1BB; CpG ODN; IL 9; Tregs; Tumor immunotherapy

Indexed keywords

4 1BB ANTIBODY; ANTINEOPLASTIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 9; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX40; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENETIC DIFFERENCE; GENETIC SELECTION; GENETIC TRANSCRIPTION; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; MICROARRAY ANALYSIS; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; ANTIGENS, CD137; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOTHERAPY; INTERLEUKIN-9; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 82355173366     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1075-6     Document Type: Article

References (45)

1. S Gross P Walden 2008 Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer Immunol Lett 116 7 14 18164076 10.1016/j.imlet.2007. 11.012 1:CAS:528:DC%2BD1cXhtl2isrg%3D
2. S Sakaguchi T Yamaguchi T Nomura M Ono 2008 Regulatory T cells and immune tolerance Cell 133 775 787 18510923 10.1016/j.cell.2008.05.009 1:CAS:528:DC%2BD1cXntFaltrg%3D (Pubitemid 351707693)
3. N Leffers MJ Gooden RA de Jong BN Hoogeboom KA ten Hoor H Hollema HM Boezen AG van der Zee T Daemen HW Nijman 2009 Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Cancer Immunol Immunother 58 449 459 18791714 10.1007/s00262-008-0583-5
4. DA Horwitz SG Zheng JD Gray 2008 Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other Trends Immunol 29 429 435 18676178 10.1016/j.it.2008.06.005 1:CAS:528: DC%2BD1cXhtVOiurbO
5. W Chen W Jin N Hardegen KJ Lei L Li N Marinos G McGrady SM Wahl 2003 Conversion of peripheral CD4 + CD25- naive T cells to CD4 + CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 J Exp Med 198 1875 1886 14676299 10.1084/jem.20030152 1:CAS:528:DC%2BD3sXpvFaktLg%3D (Pubitemid 38032120)
6. G Zhou HI Levitsky 2007 Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance J Immunol 178 2155 2162 17277120 1:CAS:528:DC%2BD2sXht1Cgu74%3D (Pubitemid 46233413)
7. J Wada H Suzuki R Fuchino A Yamasaki S Nagai K Yanai K Koga M Nakamura M Tanaka T Morisaki M Katano 2009 The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions Anticancer Res 29 881 888 19414323 1:CAS:528:DC%2BD1MXltlOqtrs%3D
8. S Onizuka I Tawara J Shimizu S Sakaguchi T Fujita E Nakayama 1999 Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody Cancer Res 59 3128 3133 10397255 1:CAS:528: DyaK1MXksVCks7s%3D (Pubitemid 29316012)
9. K Kretschmer I Apostolou P Verginis H von Boehmer 2008 Regulatory T cells and antigen-specific tolerance Chem Immunol Allergy 94 8 15 18802332 10.1159/000154846 1:CAS:528:DC%2BD1MXhsF2gurw%3D
10. AL Dominguez J Lustgarten 2008 Implications of aging and self-tolerance on the generation of immune and antitumor immune responses Cancer Res 68 5423 5431 18593945 10.1158/0008-5472.CAN-07-6436 1:CAS:528:DC%2BD1cXnvFyjtbs%3D
11. DB Hoelzinger SE Smith N Mirza AL Dominguez SZ Manrique J Lustgarten 2010 Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses J Immunol 184 6833 6842 20483762 10.4049/jimmunol.0904084 1:CAS:528:DC%2BC3cXmvFejsrc%3D
12. KN Couper PA Lanthier G Perona-Wright LW Kummer W Chen ST Smiley M Mohrs LL Johnson 2009 Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection J Immunol 182 3985 3994 19299696 10.4049/jimmunol.0803053 1:CAS:528:DC%2BD1MXjsVSjt78%3D
13. G Barton R Medzhitov 2002 Control of adaptive immune responses by Toll-like receptors Curr Opin Immunol 14 380 383 11973138 10.1016/S0952-7915(02) 00343-6 1:CAS:528:DC%2BD38XjtVeitLg%3D (Pubitemid 34327982)
14. T Kaisho S Akira 2002 Toll-like receptors as adjuvant receptors Biochim Biophy Acta 1589 1 13 10.1016/S0167-4889(01)00182-3 1:CAS:528: DC%2BD38XitFWmsbg%3D (Pubitemid 34242898)
15. Q Huang D Liu P Majewski L Schulte J Korn R Young E Lander N Hacohen 2001 The plasticity of dendritic cell responses to pathogens and their components Science 294 870 875 11679675 10.1126/science.294.5543.870 1:CAS:528: DC%2BD3MXotVCgsLw%3D (Pubitemid 33032108)
16. K Takeda S Akira 2003 Toll receptors and pathogen resistance Cell Microbiol 5 143 153 12614458 10.1046/j.1462-5822.2003.00264.x 1:CAS:528:DC%2BD3sXisVejsbk%3D (Pubitemid 36348031)
17. S Sharma AL Dominguez SZ Manrique F Cavallo S Sakaguchi J Lustgarten 2008 Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice Cancer Res 68 7530 7540 18794141 10.1158/0008-5472.CAN- 08-1635 1:CAS:528:DC%2BD1cXhtFWltb%2FP
18. TH Watts 2005 TNF/TNFR family members in costimulation of T cell responses Annu Rev Immunol 23 23 68 15771565 10.1146/annurev.immunol.23.021704. 115839 1:CAS:528:DC%2BD2MXktFOjtb0%3D (Pubitemid 40563164)
19. C Cuadros AL Dominguez GI Frost P Borgstrom J Lustgarten 2003 Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice Cancer Res 63 5895 5901 14522915 1:CAS:528:DC%2BD3sXnvVSisrk%3D (Pubitemid 37187490)
20. C Cuadros AL Dominguez PL Lollini M Croft RS Mittler P Borgstrom J Lustgarten 2005 Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice Int J Cancer 116 934 943 15856473 10.1002/ijc.21098 1:CAS:528:DC%2BD2MXpsVegtLs%3D (Pubitemid 41209201)
21. J Lustgarten AL Dominguez C Cuadros 2004 The CD8 + T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity Eur J Immunol 34 752 761 14991605 10.1002/eji.200324427 1:CAS:528:DC%2BD2cXitlGgt70%3D (Pubitemid 39255923)
22. S Rovero A Amici E Di Carlo R Bei P Nanni E Quaglino P Porcedda K Boggio A Smorlesi PL Lollini, et al. 2000 DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice J Immunol 165 5133 5142 11046045 1:CAS:528: DC%2BD3cXnvVOntr8%3D
23. J Xia Y Tanaka S Koido C Liu P Mukherjee SJ Gendler J Gong 2003 Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells J Immunol 170 1980 1986 12574367 1:CAS:528:DC%2BD3sXht12iurg%3D (Pubitemid 36197418)
24. J Fontenot J Rasmussen L Williams J Dooley A Farr A Rudensky 2005 Regulatory T cell lineage specification by the forkhead transcription factor Foxp3 Immunity 22 329 341 15780990 10.1016/j.immuni.2005.01.016 1:CAS:528:DC%2BD2MXjt1Ohsbk%3D (Pubitemid 40387475)
25. BK Choi JS Bae EM Choi WJ Kang S Sakaguchi DS Vinay BS Kwon 2004 4-1BB-dependent inhibition of immunosuppression by activated CD4 + CD25 + T cells J Leukoc Biol 75 785 791 14694186 10.1189/jlb.1003491 1:CAS:528: DC%2BD2cXjvVaku7g%3D (Pubitemid 38580058)
26. B Valzasina C Guiducci H Dislich N Killeen A Weinberg M Colombo 2005 Triggering of OX40 (CD134) on CD4(+)CD25 + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and the comparison with GITR Blood 105 2845 2851 15591118 10.1182/blood-2004-07-2959 1:CAS:528:DC%2BD2MXivFGmtL4%3D (Pubitemid 40446278)
27. RJ Noelle EC Nowak 2010 Cellular sources and immune functions of interleukin-9 Nat Rev Immunol 10 683 687 20847745 10.1038/nri2848 1:CAS:528:DC%2BC3cXhtFKrtrjK
28. JD Fontenot JP Rasmussen MA Gavin AY Rudensky 2005 A function for interleukin 2 in Foxp3-expressing regulatory T cells Nat Immunol 6 1142 1151 16227984 10.1038/ni1263 1:CAS:528:DC%2BD2MXhtFamsb%2FI (Pubitemid 41541792)
29. D Cooper P Bansal-Pakala M Croft 2002 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity Eur J Immunol 32 521 529 11828369 10.1002/1521-4141(200202)32:2<521::AID-IMMU521>3.0.CO;2-X 1:CAS:528:DC%2BD38XhvVehtLo%3D (Pubitemid 34173343)
30. S Piconese B Valzasina MP Colombo 2008 OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection J Exp Med 205 825 839 18362171 10.1084/jem.20071341 1:CAS:528:DC%2BD1cXkvVyrsrg%3D (Pubitemid 351549881)
31. S Piconese P Pittoni A Burocchi A Gorzanelli A Care C Tripodo MP Colombo 2010 A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2 Eur J Immunol 40 2902 2913 20806292 10.1002/eji.201040505
32. CE Ruby MA Yates D Hirschhorn-Cymerman P Chlebeck JD Wolchok AN Houghton H Offner AD Weinberg 2009 Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right J Immunol 183 4853 4857 19786544 10.4049/jimmunol.0901112 1:CAS:528:DC%2BD1MXht1WhsLjO
33. LF Lu EF Lind DC Gondek KA Bennett MW Gleeson K Pino-Lagos ZA Scott AJ Coyle JL Reed J Van Snick, et al. 2006 Mast cells are essential intermediaries in regulatory T-cell tolerance Nature 442 997 1002 16921386 10.1038/nature05010 1:CAS:528:DC%2BD28XovVyhtb4%3D (Pubitemid 44330250)
34. M Veldhoen C Uyttenhove J van Snick H Helmby A Westendorf J Buer B Martin C Wilhelm B Stockinger 2008 Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset Nat Immunol 9 1341 1346 18931678 10.1038/ni.1659 1:CAS:528: DC%2BD1cXhtlOjsbzL
35. W Elyaman EM Bradshaw C Uyttenhove V Dardalhon A Awasthi J Imitola E Bettelli M Oukka J van Snick JC Renauld, et al. 2009 IL-9 induces differentiation of TH17 cells and enhances function of FoxP3 + natural regulatory T cells Proc Natl Acad Sci USA 106 12885 12890 19433802 10.1073/pnas.0812530106 1:CAS:528:DC%2BD1MXhtVKlt7zL
36. A Fukushima T Yamaguchi W Ishida K Fukata RS Mittler H Yagita H Ueno 2005 Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice J Immunol 175 4897 4903 16210591 1:CAS:528: DC%2BD2MXhtVylsbrE (Pubitemid 41456371)
37. Y Sun SE Blink W Liu Y Lee B Chen J Solway J Weinstock L Chen YX Fu 2006 Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation J Immunol 177 814 821 16818735 1:CAS:528:DC%2BD28XmsVarsL4%3D (Pubitemid 44036581)
38. Y Rochman R Spolski WJ Leonard 2009 New insights into the regulation of T cells by gamma(c) family cytokines Nat Rev Immunol 9 480 490 19543225 10.1038/nri2580 1:CAS:528:DC%2BD1MXnsVylu78%3D
39. Z Yao Y Kanno M Kerenyi G Stephens L Durant WT Watford A Laurence GW Robinson EM Shevach R Moriggl, et al. 2007 Nonredundant roles for Stat5a/b in directly regulating Foxp3 Blood 109 4368 4375 17227828 10.1182/blood-2006-11- 055756 1:CAS:528:DC%2BD2sXls1amsL4%3D (Pubitemid 46743405)
40. MA Burchill J Yang C Vogtenhuber BR Blazar MA Farrar 2007 IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3 + regulatory T cells J Immunol 178 280 290 17182565 1:CAS:528:DC%2BD2sXnvVWj (Pubitemid 46033611)
41. JM Townsend GP Fallon JD Matthews P Smith EH Jolin NA McKenzie 2000 IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development Immunity 13 573 583 11070175 10.1016/S1074-7613(00)00056-X 1:CAS:528:DC%2BD3cXnsl2nt7o%3D
42. S Sharma AL Dominguez DB Hoelzinger J Lustgarten 2008 CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged Cancer Immunol Immunother 57 549 561 17828396 10.1007/s00262-007-0393-1 1:CAS:528:DC%2BD1cXhtV2ju7Y%3D (Pubitemid 351170538)
43. K Eller D Wolf JM Huber M Metz G Mayer AN McKenzie M Maurer AR Rosenkranz AM Wolf 2011 IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression J Immunol 186 83 91 21115728 10.4049/jimmunol.1001183 1:CAS:528:DC%2BC3cXhs1ajtLbI
44. EC Nowak CT Weaver H Turner S Begum-Haque B Becher B Schreiner AJ Coyle LH Kasper RJ Noelle 2009 IL-9 as a mediator of Th17-driven inflammatory disease J Exp Med 206 1653 1660 19596803 10.1084/jem.20090246 1:CAS:528: DC%2BD1MXps1enurs%3D
45. B White F Leon W White G Robbie 2009 Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers Clin Ther 31 728 740 19446146 10.1016/j.clinthera.2009.04.019 1:CAS:528:DC%2BD1MXmsFelsLw%3D